Regeneron

Regeneron, founded in 1988, is a prominent biotechnology firm specializing in the discovery, development, and commercialization of innovative medicines for serious diseases. The company leverages advanced science and proprietary technologies to address critical medical needs, focusing on therapeutic areas such as oncology, inflammatory disorders, cardiovascular disease, and rare conditions. By integrating biopharmaceutical research with clinical development, Regeneron maintains a robust pipeline of monoclonal antibodies and novel drug candidates designed to improve patient outcomes globally.

Operating with a workforce of over 10,000 employees, Regeneron maintains a significant operational footprint across four primary locations. The company’s commitment to scientific excellence is supported by its state-of-the-art infrastructure and research facilities. Learn about Regeneron's global headquarters for detailed information regarding their geographic presence and operational capabilities in Tarrytown, New York. This strategic positioning allows the firm to effectively manage its complex drug discovery processes and maintain its competitive edge within the global pharmaceutical landscape.

Regeneron demonstrates strong market performance, reporting annual revenue of $14.9B. The company competes with major industry players such as Amgen, Sanofi, and Novartis, consistently pushing the boundaries of genomic discovery and therapeutic innovation. Meet Regeneron's team to gain insights into the leadership driving these advancements, or Explore financial highlights for a comprehensive overview of their fiscal metrics and funding history. As a publicly traded entity on the NASDAQ under the ticker REGN, the firm continues to prioritize sustainable growth and the delivery of life-changing treatments to patients worldwide.